IQVH Stock Overview
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
IQVIA Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$185.70 |
| 52 Week High | US$238.00 |
| 52 Week Low | US$178.85 |
| Beta | 1.51 |
| 11 Month Change | -12.45% |
| 3 Month Change | -16.50% |
| 1 Year Change | -3.48% |
| 33 Year Change | -22.01% |
| 5 Year Change | 37.56% |
| Change since IPO | 39.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| IQVH | AT Life Sciences | AT Market | |
|---|---|---|---|
| 7D | -4.9% | -6.1% | -0.2% |
| 1Y | -3.5% | 2.0% | 2.3% |
Return vs Industry: IQVH underperformed the Austrian Life Sciences industry which returned 1.4% over the past year.
Return vs Market: IQVH underperformed the Austrian Market which returned 1.2% over the past year.
Price Volatility
| IQVH volatility | |
|---|---|
| IQVH Average Weekly Movement | 4.2% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.5% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: IQVH has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: IQVH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 88,000 | Ari Bousbib | www.iqvia.com |
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
IQVIA Holdings Inc. Fundamentals Summary
| IQVH fundamental statistics | |
|---|---|
| Market cap | €33.66b |
| Earnings (TTM) | €1.34b |
| Revenue (TTM) | €14.61b |
25.5x
P/E Ratio2.3x
P/S RatioIs IQVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IQVH income statement (TTM) | |
|---|---|
| Revenue | US$15.32b |
| Cost of Revenue | US$9.93b |
| Gross Profit | US$5.39b |
| Other Expenses | US$3.98b |
| Earnings | US$1.41b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.74 |
| Gross Margin | 35.17% |
| Net Profit Margin | 9.17% |
| Debt/Equity Ratio | 194.9% |
How did IQVH perform over the long term?
See historical performance and comparison